About the Authors
- Roger J. Bedimo
-
* E-mail: roger.bedimo@va.gov
Affiliation Department of Medicine, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
- Henning Drechsler
-
Affiliation Department of Medicine, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
- Mamta Jain
-
Affiliation Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
- James Cutrell
-
Affiliation Department of Medicine, VA North Texas Health Care System, Dallas, Texas, United States of America
- Song Zhang
-
Affiliation Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
- Xilong Li
-
Affiliation Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
- Irfan Farukhi
-
Affiliation Department of Nuclear Medicine, VA North Texas Health Care System, Dallas, Texas, United States of America
- Rosinda Castanon
-
Affiliation Department of Nuclear Medicine, VA North Texas Health Care System, Dallas, Texas, United States of America
- Pablo Tebas
-
Affiliation Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
- Naim M. Maalouf
-
Affiliation Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
Competing Interests
Roger Bedimo has received research grants from Merck & Co, Janssen Therapeutics, and Bristol Myers Squibb. He’s also on ad-hoc scientific advisory boards for Janssen Therapeutics, ViiV Health Care, and Bristol Myers Squibb. Pablo Tebas is consultant for Merck & Co. and Gilead, speaker for Janssen Therapeutics and is on the adjudication committee for GSK. This specific study was funded by grants from Merck & Co, and Janssen Therapeutics to the VA North Texas Health Care System for Roger Bedimo. Raltegravir is a drug produced by Merck & Co. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: RB. Performed the experiments: RB HD MJ JC RC IF NM. Analyzed the data: RB HD JC SZ XL NM PT. Contributed reagents/materials/analysis tools: RB HD IF NM. Wrote the paper: RB HD PT NM JC.